These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20021541)

  • 1. Do the current medical and economic times dictate the need for the "polypill"?
    Rifai L; Khan BV
    J Clin Hypertens (Greenwich); 2009 Dec; 11(12):775-6. PubMed ID: 20021541
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefits, challenges, and registerability of the polypill.
    Sleight P; Pouleur H; Zannad F
    Eur Heart J; 2006 Jul; 27(14):1651-6. PubMed ID: 16603580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panacea in a pill?
    Amsterdam EA
    Prev Cardiol; 2004; 7(1):46-7. PubMed ID: 15010628
    [No Abstract]   [Full Text] [Related]  

  • 4. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH; Bestwick JP; Wald DS
    Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflections on the regulation of the Polypill.
    Forslund L
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):94-5. PubMed ID: 19047991
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hypertension therapies compared. Are the new nevertheless better than the old?].
    MMW Fortschr Med; 2005 Mar; 147(12):6, 8. PubMed ID: 15832780
    [No Abstract]   [Full Text] [Related]  

  • 8. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
    Chao J; Bansilal S
    Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
    [No Abstract]   [Full Text] [Related]  

  • 9. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
    Xavier D; Pais P; Sigamani A; Pogue J; Afzal R; Yusuf S;
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):96-7. PubMed ID: 19104516
    [No Abstract]   [Full Text] [Related]  

  • 10. The Polypill in the prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
    [No Abstract]   [Full Text] [Related]  

  • 11. Polypill: for Pollyanna.
    Spence JD
    Int J Stroke; 2008 May; 3(2):92-7. PubMed ID: 18706002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rational approach to hypertension treatment in the older patient.
    Flack JM; Woolley A; Esunge P; Grimm RH
    Geriatrics; 1992 Nov; 47(11):24-8, 33-8. PubMed ID: 1358761
    [No Abstract]   [Full Text] [Related]  

  • 13. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
    Joshi SR
    J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
    ; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
    Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of essential arterial hypertension].
    Girerd X
    Presse Med; 2000 Nov; 29(34):1856-8. PubMed ID: 11709818
    [No Abstract]   [Full Text] [Related]  

  • 17. News of the polypill.
    Marshall T
    BMJ; 2008 Oct; 337():a2160. PubMed ID: 18936068
    [No Abstract]   [Full Text] [Related]  

  • 18. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypill in cardiovascular disease: has it's time come?
    Kuppuswamy V; Choo WK; Gupta S
    Indian Heart J; 2009; 61(4):322-7. PubMed ID: 20635733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.